These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 18612674

  • 1. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.
    Arch JR.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Aug; 378(2):225-40. PubMed ID: 18612674
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
    Arch JR.
    Eur J Pharmacol; 2002 Apr 12; 440(2-3):99-107. PubMed ID: 12007528
    [Abstract] [Full Text] [Related]

  • 4. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
    Weyer C, Tataranni PA, Snitker S, Danforth E, Ravussin E.
    Diabetes; 1998 Oct 12; 47(10):1555-61. PubMed ID: 9753292
    [Abstract] [Full Text] [Related]

  • 5. Hibiscus sabdariffa Linn. Extract Increases the mRNA Expression of the Arcuate Nucleus Leptin Receptor and is Predicted in silico as an Anti-obesity Agent.
    Kartinah NT, Anggraini S, Fadilah F, Rickie R.
    Curr Comput Aided Drug Des; 2024 Oct 12; 20(6):811-821. PubMed ID: 37608673
    [Abstract] [Full Text] [Related]

  • 6. Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats.
    Decara J, Rivera P, Arrabal S, Vargas A, Serrano A, Pavón FJ, Dieguez C, Nogueiras R, Rodríguez de Fonseca F, Suárez J.
    Acta Physiol (Oxf); 2018 Apr 12; 222(4):e13008. PubMed ID: 29193738
    [Abstract] [Full Text] [Related]

  • 7. CNS β3-adrenergic receptor activation regulates feeding behavior, white fat browning, and body weight.
    Richard JE, López-Ferreras L, Chanclón B, Eerola K, Micallef P, Skibicka KP, Wernstedt Asterholm I.
    Am J Physiol Endocrinol Metab; 2017 Sep 01; 313(3):E344-E358. PubMed ID: 28588096
    [Abstract] [Full Text] [Related]

  • 8. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
    de Souza CJ, Burkey BF.
    Curr Pharm Des; 2001 Sep 01; 7(14):1433-49. PubMed ID: 11472270
    [Abstract] [Full Text] [Related]

  • 9. Up-regulation of a thermogenesis-related gene (UCP1) and down-regulation of PPARgamma and aP2 genes in adipose tissue: possible features of the antiobesity effects of a beta3-adrenergic agonist.
    Margareto J, Larrarte E, Marti A, Martinez JA.
    Biochem Pharmacol; 2001 Jun 15; 61(12):1471-8. PubMed ID: 11377376
    [Abstract] [Full Text] [Related]

  • 10. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
    Weyer C, Gautier JF, Danforth E.
    Diabetes Metab; 1999 Mar 15; 25(1):11-21. PubMed ID: 10335419
    [Abstract] [Full Text] [Related]

  • 11. Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats.
    Alemzadeh R, Karlstad MD, Tushaus K, Buchholz M.
    Metabolism; 2008 Nov 15; 57(11):1597-607. PubMed ID: 18940400
    [Abstract] [Full Text] [Related]

  • 12. Thermogenesis and related metabolic targets in anti-diabetic therapy.
    Arch JR.
    Handb Exp Pharmacol; 2011 Nov 15; (203):201-55. PubMed ID: 21484574
    [Abstract] [Full Text] [Related]

  • 13. Leptin and the OB-receptor as anti-obesity target: recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti- obesity lead compounds.
    Tutone M, Lauria A, Almerico AM.
    Curr Pharm Des; 2014 Nov 15; 20(1):136-45. PubMed ID: 24180400
    [Abstract] [Full Text] [Related]

  • 14. [beta 3-adrenergic receptor agonists as anti-obese and anti-diabetic drugs].
    Sakura H, Togashi M, Iwamoto Y.
    Nihon Rinsho; 2002 Jan 15; 60(1):123-9. PubMed ID: 11808322
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Advances in pharmacotherapy for obesity.
    Carruba M, Tomello C, Briscini L, Nisoli E.
    Int J Obes Relat Metab Disord; 1998 Aug 15; 22 Suppl 1():S13-6; discussion S17. PubMed ID: 9758239
    [Abstract] [Full Text] [Related]

  • 18. The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis.
    Collins S, Surwit RS.
    Recent Prog Horm Res; 2001 Aug 15; 56():309-28. PubMed ID: 11237219
    [Abstract] [Full Text] [Related]

  • 19. Effects of ZD7114, a selective beta3-adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance.
    Savontaus E, Pesonen U, Rouru J, Huupponen R, Koulu M.
    Eur J Pharmacol; 1998 Apr 24; 347(2-3):265-74. PubMed ID: 9653893
    [Abstract] [Full Text] [Related]

  • 20. Beta3-adrenergic regulation of leptin, food intake, and adiposity is impaired with age.
    Kumar MV, Moore RL, Scarpace PJ.
    Pflugers Arch; 1999 Oct 24; 438(5):681-8. PubMed ID: 10555566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.